icotec Receives US Medicare Approval for Spinal Implant Technology
US health authority CMS has approved icotec's CMORE® CT spinal implant system for New Technology Add-On Payment (NTAP). The approval takes effect October 1, 2026, expanding access to the company's radiolucent stabilization technology.
The US Centers for Medicare & Medicaid Services (CMS) has granted icotec approval for a New Technology Add-On Payment (NTAP) for its CMORE® CT cervical-thoracic spinal implant system. This decision, effective October 1, 2026, will expand access to the company's radiolucent spinal stabilization technology for eligible Medicare procedures.
The NTAP designation provides hospitals with additional reimbursement when they use new, substantially similar technologies to treat Medicare beneficiaries. icotec's CMORE® CT system is a Class III implant designed for cervical and thoracic spine stabilization. Its radiolucent material is intended to allow for clearer post-operative imaging, potentially aiding in patient monitoring and follow-up care.
This approval signifies recognition of the system's potential to improve patient outcomes compared to existing treatments. icotec previously received FDA clearance for its technology, which facilitated market entry in the United States. The company anticipates that the NTAP status will significantly increase the adoption of the CMORE® CT system among Medicare patients.
icotec aims to enhance the results of spinal surgery and reduce patient recovery times. The company views its radiolucent technology as a key factor in achieving these goals and plans to continue developing its product offerings and expanding its market reach.